1. Clinical & Scientific Overview
Finasteride (and Dutasteride comparison) (TIP-MED-000234, Reference Code [12.2]) is classified under
Urological & Renal Stone Medicines (Ch 12) as a 5-Alpha-Reductase Inhibitor (5-ARI; Blocks Intracellular Conversion of Testosterone to Potent Dihydrotestosterone [DHT] to Shrink Prostate Volume).
Within the Indian regulatory and compendial framework, it is governed under Schedule H Prescription Drug (To be sold by retail on the prescription of a Registered Medical Practitioner only — Drugs Rules 1945).
Representative Indian Market Examples (Edition 2.7 Ch 12 [12.2], p. 155): Finasteride (Type-2 5-ARI): Finast (Dr. Reddy's—5 mg), Fincar (Cipla—5 mg), Finpecia (Cipla—1 mg for alopecia); Dutasteride (Dual Type-1 & Type-2 5-ARI, 0.5 mg): Duprost (Cipla), Veltride (Intas); In FDC with Tamsulosin: Urimax-D / Veltam-Plus (Tamsulosin 0.4 mg + Dutasteride 0.5 mg), Urimax-F (Tamsulosin 0.4 mg + Finasteride 5 mg) — Strengths & Dosage Forms: Finasteride Film-Coated Tablets: 5 mg (BPH), 1 mg (Androgenetic Alopecia); Dutasteride Softgel Capsules: 0.5 mg (BPH)
Finasteride Film-Coated Tablets: 5 mg (BPH), 1 mg (Androgenetic Alopecia); Dutasteride Softgel Capsules: 0.5 mg (BPH)
3. Mechanism of Action & Pharmacodynamics
5-Alpha-Reductase Inhibitor (5-ARI; Blocks Intracellular Conversion of Testosterone to Potent Dihydrotestosterone [DHT] to Shrink Prostate Volume) acting on target receptor/enzyme pathways in Urological & Renal Stone Medicines (Ch 12): clinical efficacy is mediated via 5-Alpha-Reductase Inhibitor (5-ARI; Blocks Intracellular Conversion of Testosterone to Potent Dihydrotestosterone [DHT] to Shrink Prostate Volume) for Treatment and long-term progression prevention of moderate-to-severe Benign Prostatic Hyperplasia (BPH) with an enlarged prostate (>30–40 mL/grams)—uniquely shrinks prostate gland volume by 20–30%, reduces risk of Acute Urinary Retention (AUR) by >50%, and reduces need for TURP prostate surgery! (1 mg strength: male pattern baldness)..
4. Therapeutic Indications & Evidence-Supported Uses
- Treatment and long-term progression prevention of moderate-to-severe Benign Prostatic Hyperplasia (BPH) with an enlarged prostate (>30–40 mL/grams)—uniquely shrinks prostate gland volume by 20–30%, reduces risk of Acute Urinary Retention (AUR) by >50%, and reduces need for TURP prostate surgery! (1 mg strength: male pattern baldness)
🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.
5. Educational Dosage Context, Formulations & Administration
Educational Dosing & Regimen Summary: General Adult Reference: BPH: Finasteride 5 mg once daily (OR Dutasteride 0.5 mg once daily), alone or combined with Tamsulosin 0.4 mg. Follow urologist prescription.
Administration & Meal Timing: Plain Finasteride/Dutasteride: With or without food. If in FDC with Tamsulosin (Urimax-D / Urimax-F / Veltam-Plus): MUST be taken 30 minutes AFTER dinner! Swallow whole. | Once daily (in the evening 30 minutes after dinner if combined with tamsulosin).
6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment
Absorption, distribution, metabolism, and excretion follow class pharmacokinetic profile; verify patient renal/hepatic function.
Renal: Excreted as metabolites in faeces/urine; no dose adjustment required across any stage of CKD. Hepatic: Metabolised extensively in the liver (Note: Dutasteride has an extraordinarily long elimination half-life of 3 to 5 WEEKS vs Finasteride's 6–8 hours!)—use caution in liver disease and avoid in severe hepatic impairment.
Renal: Excreted as metabolites in faeces/urine; no dose adjustment required across any stage of CKD. Hepatic: Metabolised extensively in the liver (Note: Dutasteride has an extraordinarily long elimination half-life of 3 to 5 WEEKS vs Finasteride's 6–8 hours!)—use caution in liver disease and avoid in severe hepatic impairment.
Renal: Excreted as metabolites in faeces/urine; no dose adjustment required across any stage of CKD. Hepatic: Metabolised extensively in the liver (Note: Dutasteride has an extraordinarily long elimination half-life of 3 to 5 WEEKS vs Finasteride's 6–8 hours!)—use caution in liver disease and avoid in severe hepatic impairment.
7. Contraindications, Precautions & High-Risk Warnings
- 1. STRICT PREGNANCY TERATOGENICITY HANDLING BAN (Category X): Finasteride and Dutasteride inhibit DHT-dependent external genitalia differentiation in a male foetus (causing hypospadias/ambiguous genitalia)! Women who are pregnant or may become pregnant MUST NEVER take or even touch crushed, broken, or leaking Finasteride tablets or Dutasteride capsules (absorbed through skin)! 2. CRITICAL PROSTATE CANCER (PSA) MASKING RULE: Finasteride and Dutasteride reduce Serum Prostate-Specific Antigen (PSA) levels by approximately 50% within 6 months—even in the presence of prostate cancer!
Key Clinical Precautions: Renal: Excreted as metabolites in faeces/urine; no dose adjustment required across any stage of CKD. Hepatic: Metabolised extensively in the liver (Note: Dutasteride has an extraordinarily long elimination half-life of 3 to 5 WEEKS vs Finasteride's 6–8 hours!)—use caution in liver disease and avoid in severe hepatic impairment.
8. Adverse Effects Profile
- Decreased libido (3–6%), erectile dysfunction (5–8%), ejaculatory disorders / decreased semen volume, mild gynaecomastia (breast enlargement/tenderness in 1–2% of men).
- Male Breast Cancer (rare—instruct patients to report any unilateral breast lump, pain, or nipple discharge immediately!), depression/suicidal ideation (post-finasteride mood warning), high-grade prostate cancer detection delay if PSA is not doubled during interpretation, angioedema.
- Monitor for severe hypersensitivity, organ toxicity, or dose-limiting adverse events.
9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions
- Minimal pharmacokinetic interactions (metabolised by CYP3A4 without inducing/inhibiting enzymes; itraconazole/diltiazem modestly raise dutasteride levels)
10. Clinical Monitoring, Patient Counselling & Storage
Clinical & Laboratory Monitoring: Monitor clinical response, baseline renal/hepatic parameters, and relevant serum biomarkers.
Pharmacist Patient Counselling Points:
- Patient Counselling Checklist: 3 Vital Counselling Points for Finast / Duprost / Urimax-D: 1. The 'PSA Doubling Rule' for Lab Reports: Tell every elderly gentleman: 'Whenever you get a PSA blood test for your prostate after taking Finasteride or Dutasteride for 6+ months, remind your doctor that you take this medicine—because this tablet cuts the PSA number in half, the doctor must MULTIPLY your lab PSA value by 2 to get your true PSA!' Furthermore, any rise in PSA while taking Finasteride/Dutasteride requires urgent urology review! 2. 6-Month Patience Rule: Do not stop the tablet after 1 month thinking it didn't shrink the prostate—gland shrinkage takes 3 to 6 months. 3. Pregnant daughters-in-law or female caregivers must never handle broken tablets or leaking capsules.
- Meal & Clock Timing Instruction: Plain Finasteride/Dutasteride: With or without food. If in FDC with Tamsulosin (Urimax-D / Urimax-F / Veltam-Plus): MUST be taken 30 minutes AFTER dinner! Swallow whole. (Once daily (in the evening 30 minutes after dinner if combined with tamsulosin).)
- Missed Dose Protocol: Take as soon as remembered on the same day; skip if close to next day's dose. Never double.
- Geriatric Dispensing Pearl: Highly beneficial in elderly men with large prostates (>40 g) to prevent emergency catheterisation for acute urinary retention; always remind them about the PSA-doubling rule and breast lump check.
Storage, Stability & Dispensing Safeguards: Store below 25°C–30°C in original moisture- and light-resistant packaging out of reach of children. Available forms: Finasteride Film-Coated Tablets: 5 mg (BPH), 1 mg (Androgenetic Alopecia); Dutasteride Softgel Capsules: 0.5 mg (BPH)
11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)
12. Authoritative References, Regulatory Sources & Editorial Disclaimer
Primary Compendial & Guideline Reference: Indian Pharmacist Desk Reference — Professional Edition 2.7 (2026–27) • Ch 12 [12.2] (p. 155)
Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)
Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: HANDBOOK_SOURCE_CONTENT
Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.
13. Related Reference Monographs, Educational Guides & Visual Concept
💊 Related Pharmacological / Category Profiles
- [12.10]-C157 Oxybutynin Chloride — Competitive Muscarinic (M2/M3) Receptor Antagonists & Direct Smoo
- [12.10]-C158 Flavoxate Hydrochloride — Competitive Muscarinic (M2/M3) Receptor Antagonists & Direct Smoo
- [12.10]-CMP159 Drotaverine Hydrochloride IP — Competitive Muscarinic (M2/M3) Receptor Antagonists & Direct Smoo
- [12.11]-C160 Disodium Hydrogen Citrate — Systemic & Urinary Alkalinisers / Urolithiasis Inhibitors